Aliskiren-hydrochlorothiazide combination for the treatment of hypertension

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 3, 2008, Pages 305-314

  Chrysant, Steven G ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Oklahoma Cardiovascular and Hypertension Center   (United States)

Author keywords

Aliskiren hydrochlorothiazide; Combination therapy; Hypertension

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MEVINOLIN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN; RENIN INHIBITOR; VALSARTAN; WARFARIN; AMIDE; FUMARIC ACID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; IC 50; KIDNEY DISEASE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORTALITY; NONHUMAN; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; DRUG ADMINISTRATION; DRUG APPROVAL; DRUG COMBINATION; DRUG INTERACTION; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

AMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41449118358     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.3.305     Document Type: Article

References (54)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lan KS. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. Hypertension 49, 69-75 (2007).
2. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
3. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328, 914-921 (1993).
4. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. 4, 393-404 (2002).
5. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch. Intern. Med. 154, 737-743 (1994).
6. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17, 252-259(2003).
7. Tiegerstedt R, Bergman PG. Niere und Kreislaub. Skandindvisches Archiv für Physiologie 8, 223-271 (1898).
8. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now and where are we going? J. Hypertens. 24, 243-256 (2006).
9. Messerli FH, Re RN. Do we need yet another blocker of the renin-angiotensin system? J. Am. Coll. Cardiol. 49, 1164-1165 (2007).
10. Sealey JE, Laragh JH. Aliskiren, first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens. 20, 587-597 (2007).
11. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol. 1, 221-228 (2006).
12. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705 (2003).
13. Waldmeir FJ, Glaeznel U, Wirz B et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos. 35, 1418-1428 (2007).
14. Vaidyanathan S, Jermany J, Yeh CM, Bizot M-N, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol. 62, 690-698 (2006).
15. Vaidyanathan S. Warren V, Yeh CM, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J. Clin. Pharmacol. 47, 192-200 (2007).
16. Vaidyanathan S, Bigler H, Yeh CM et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin. Pharmacokinet. 46, 661-675 (2007).
17. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker. Hypertension 49, 276-284 (2007).
18. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens. 23, 417-426 (2005).
19. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Dieterich HA. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type II diabetes mellitus. Clin. Pharmacokinet. 45, 1125-1134 (2006).
20. Viadyanathan S, Reynolds C, Yeh CM et al. Pharmacokinetics, safety and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J. Clin. Pharmacol. 47, 453-460 (2007).
21. Danser AHJ, Deinum J. Renin, pro-renin, and the putative (pro) renin receptor. Hypertension 46, 1069-1076 (2005).
22. Sepehrdad R, Frishman WH, Stier CT, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy focus on aliskiren. Cardiol. Rev. 15, 242-256 (2007).
23. Nguyen G, Delarue F, Burckle C, Bouzhir L, Gillet T, Sraer J-D. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
24. Van Kasteren CAM, Danser AHJ, Derkx FHM et al. Manose-6-phosphate receptor-mediated internalization and activation of pro-renin by cardiac cells. Hypertension 30, 1389-1396 (1997).
25. Vandeneunden MMED, Saris JJ, deBruin RJA et al. Pro-renin accumulation and activation in human endothelial cells. Importance of manose-6-phosphate receptors. Arterioscler. Thromb. Vasc. Biol. 21, 911-916 (2001).
26. Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr. Opin. Pharmacol. Epub ahead of print (2008).
27. Menard J, Guyene TT, Chatellier G, Kleinbloessen CH, Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 18, 257-265 (1991).
28. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576 (2005).
29. Nussberger J, Wuerzner G, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1-E8 (2002).
30. Azizi M, Menard J, Bissery A, Guyenne TT, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 15, 3126-3133 (2004).
31. Frampton JE, Curran MP. Aliskiren: A review of its use in the management of hypertension. Drugs 67, 1767-1792 (2007).
32. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 58, 433-436 (2004).
33. Vaidyanathan S, Valencia J, Kemp C et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. 60, 1343-1356 (2006).
34. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmocol. Ther. 43, 527-535 (2005).
35. Kushiro T, Itakura H, Gotou H, Terao S, Keefe DL, Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens. Res. 29, 997-1005 (2006).
36. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 49, 1157-1163 (2007).
37. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25, 217-226 (2007).
38. Jordan J, Engeli S, Boye SW, Lebreton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 49, 1047-1055 (2007).
39. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with the oral renin inhibitor, aliskiren. Hypertension 42, 1137-1143 (2003).
40. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018 (2005).
41. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combinacion with valsartan. Am. J. Hypertens. 20, 11-20 (2007).
42. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined-use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370, 221-229 (2007).
43. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45, 880-886 (2005).
44. Menard J, Azizi M. The difficult conception, birth and delivery of renin inhibitor: controversies around aliskiren. J. Hypertens. 25, 1775-1782 (2007).
45. Schmieder RE. The potential role of prorenin in diabetic nephropathy. J. Hypertens. 25, 1323-2328 (2007).
46. Ganten D, Wagner J, Bader M et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl Acad. Sci. USA 89, 7806-7810 (1992).
47. Takahashi H, Ichibara A, Kaneshiro, Y et al. Regression of nephropathy developed in diabetes by (pro) renin receptor blockade. J. Am. Soc. Nephrol. 18, 2054-2061 (2007).
48. Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 370, 195-196 (2007).
49. Bühler FR, Laragh JH, Baer L, Vaughan ED Jr, Burnner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypotensive diseases. N. Engl. J. Med. 287, 1209-1214 (1972).
50. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens. 12, 451-459 (1999).
51. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today 40, 791-801 (2004).
52. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J. Hum. Hypertens. 19, 923-931 (2005).
53. Victor RG. Pathophysiology of target-organ disease. Does angiotensin II remain the key? J. Clin. Hypertens. 9(Suppl. 4), 4-10 (2007).
54. Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev. Cardiovasc. Ther. 1(3), 335-343 (2003).